Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for Cognitive Dysfunction in Schizophrenia
NCT00588731Phase 2Completed
- Sponsor
- Yale University
- Start
- Feb 2009
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia and schizoaffective disorder comparing Cannabidiol Arm with Placebo Arm (2 arms). Primary endpoint: Verbal Short Term Memory at 6 weeks. Started Feb 2009; status: completed.
02
Drugs
cannabidiol
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00588731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00588731.